Vincerx Pharma, Inc.

NasdaqCM VINC

Vincerx Pharma, Inc. Market Capitalization on February 05, 2025: USD 3.25 M

Vincerx Pharma, Inc. Market Capitalization is USD 3.25 M on February 05, 2025, a 852.07% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Vincerx Pharma, Inc. 52-week high Market Capitalization is USD 4.66 M on January 24, 2025, which is 43.45% above the current Market Capitalization.
Vincerx Pharma, Inc. 52-week low Market Capitalization is USD 249.49 K on January 22, 2025, which is -92.32% below the current Market Capitalization.
Vincerx Pharma, Inc. average Market Capitalization for the last 52 weeks is USD 2.65 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqCM: VINC

Vincerx Pharma, Inc.

CEO	Dr. Raquel E. Izumi Ph.D.
IPO Date	May 27, 2020
Location	United States
Headquarters	260 Sheridan Avenue
Employees	42
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Key trends

Past 5 years